Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
What's Going On With Tempus AI Stock Today?

What's Going On With Tempus AI Stock Today?

FinvizFinviz2026/02/18 16:15
By:Finviz

Tempus AI (NASDAQ:TEM) rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors.

The next-generation model analyzes gene expression to help identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering what the company says is a more dynamic assessment of tumor biology than traditional genomic methods. In a real-world validation study, HRD-RNA–positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens saw a significant reduction in mortality risk compared with those receiving non-platinum therapies.

Tempus plans to make the test clinically available later this year. Chief Development Officer Halla Nimeiri said the algorithm provides physicians with a more functional view of HRD status by examining the transcriptome rather than the genome alone.

The announcement follows Tempus' recent non-exclusive distribution agreement with Median Technologies to expand AI-driven cancer diagnostics through the eyonis platform. Broader tech stocks also edged higher in the prior session, providing a supportive backdrop for the move.

Technical Analysis

Currently, the stock is trading 8.3% below its 20-day simple moving average (SMA) and 25.8% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased 35.86% over the past 12 months and are positioned closer to their 52-week lows than highs.

The RSI is at 35.53, which is considered neutral territory, while the MACD shows a value of -3.9401, below its signal line at -3.3917, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s near-term performance.

  • Key Resistance: $61.50
  • Key Support: $50.00

The launch of the HRD-RNA algorithm highlights Tempus’s commitment to leveraging AI in healthcare to enhance treatment options for patients. This innovative approach positions the company as a leader in precision medicine, potentially improving patient outcomes and expanding its market reach.

Earnings & Analyst Outlook

The countdown is on: Tempus AI is set to report earnings on February 24, 2026.

  • EPS Estimate: Loss of 13 cents (Up from Loss of 18 cents YoY)
  • Revenue Estimate: $364.25 million (Up from $200.68 million YoY)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $76.60. Recent analyst moves include:

  • Baird: Initiated with Outperform (Target $59.00) (Feb. 17)
  • Canaccord Genuity: Buy (Lowers Target to $80.00) (Dec. 22, 2025)
  • JP Morgan: Neutral (Lowers Target to $80.00) (Dec. 15, 2025)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Weak (Score: 5.75) — Stock is underperforming the broader market.

The Verdict: Tempus AI’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the weak momentum score indicates underperformance, innovative developments in precision medicine could catalyze future growth.

Top ETF Exposure

  • ARK Innovation ETF (NYSE:ARKK): 5.07% Weight
  • ARK Genomic Revolution ETF (BATS:ARKG): 8.63% Weight

Significance: Because TEM carries significant weight in these funds, any significant inflows or outflows will likely trigger automatic buying or selling of the stock.

TEM Price Action: Tempus AI shares were up 3.41% at $54.35 during premarket trading on Wednesday, according to Benzinga Pro data.

Image: Shutterstock

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Sovereign bond yields hit highest since 2008! US and Japanese government bonds break key levels, why is the global bond market collapsing across the board?

The yield on 10-year US Treasury bonds has surged past 4.78%, approaching the 5% threshold, while the yield on 10-year Japanese bonds has touched 3% for the first time in 30 years. The simultaneous breakout of these two global benchmark sovereign bonds reflects concentrated macroeconomic pressures: Middle East conflicts have pushed oil prices back up to $90, Federal Reserve Chair Powell's hawkish stance has suppressed expectations for interest rate cuts, and a record-high $40 trillion US debt supply and the Bank of Japan's imminent tightening have together created extreme liquidity squeezes on both the supply and demand sides globally.

华尔街见闻2026/09/01 07:21